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Abstract
Background: Idiopathic granulomatous mastitis (IGM) is a rare chronic inflammatory dis-
ease of the breast with unknown aetiology. Its treatment is controversial and the recurrence
rate is high. The objectives of this study were to examine the demographic, sociocultural
and clinical characteristics observed among a large cohort of IGM patients from Turkey and
to identify factors related to the recurrence of IGM.
Methods: The study was designed as a multicentre retrospective study including 22 breast cen-
tres in Turkey. A total of 720 IGM patients are included in the study. Patient data were obtained
from the patient’s files and electronic records based on the study protocol. Patients’ demographic,
clinical, radiological, treatment and recurrence of IGM related characteristics were recorded.
Results: Our results revealed a statistically significant association between IGM recurrence
and history of pregnancy, breastfeeding, breast infection and smoking (P < 0.05). Having a
chronic systematic disease, oral contraceptive, analgesic and herbal medicine consumptions,
treatment choice, education, place of birth and current residence were not found to be asso-
ciated with IGM recurrence (P > 0.05).
Conclusion: Our findings show that history of pregnancy, breastfeeding, breast infection
and smoking were the risk factors for IGM recurrence. As current treatment methods did
not affect IGM recurrence, recurrence-related factors, such as breast infection and smoking,
should be considered to eliminate while focusing on less invasive local treatment research.
Introduction
Idiopathic granulomatous mastitis (IGM) is a rare chronic inflamma-
tory disease of the breast. It was first defined by Kessler and Wolloch
in 1972.1 It typically affects young women between 17 and 42 years
of age within the reproductive and post-child-bearing period. IGM
comprises 24% of all inflammatory diseases of the breast.2
The annual prevalence and incidence of IGM have been reported
as 2.4 per 100 000 women and 0.37%, respectively.3,4 Although its
prevalence in Turkey has not been clearly established, it is thought
to be higher than in the USA.5
Although IGM is a benign disease, it mimics breast cancer, both
clinically and radiologically.6 As IGM has the same radiological
characteristics with breast cancer, dilemmas are observed in the
diagnosis.7 Precise diagnosis may only be confirmed histopatholo-
gically in IGM.8,9
The treatment of IGM is still a debate. Currently, there is no univer-
sally accepted treatment strategy. Local and systemic corticosteroids
and antibiotics are the most frequently used agents in the medical treat-
ment. However, successful results have been reported with agents,
such as methotrexate, azathioprine, glucocorticoids, bromocriptine and
colchicine.10–12 Surgical treatment of IGM includes abscess drainage,
local and wide excisions, or mastectomy. Better outcomes have been
reported with steroid addition to the surgical treatment.13
The aetiology of IGM is not fully understood. However, autoim-
mune diseases, hormone irregularities, local immune response to
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trauma, local irritants, undetected organisms, viruses, hyperprolacti-
nemia, diabetes, α-1-antitrypsin deficiency, smoking, ductal ectasis
and oral contraceptive use have been blamed as the aetiology.14
Additionally, sarcoidosis, tuberculosis, foreign substances and cory-
nebacterial infections have been blamed for the aetiology.15
Recurrence may be observed despite broad surgical excision in
IGM. The IGM recurrence rate varies between 5% and 50%
according to the literature.16–18 Post-excision recurrence may be as
high as 50%.5 It is important to know the factors affecting recur-
rence as much as the aetiological factors in the fight against IGM.
Analysing the effects of demographic and clinical characteristics
along with the aetiological factors on the IGM recurrence may con-
tribute to the decrease in post-treatment recurrence. Therefore, deter-
mination of IGM-related aetiological, clinical and epidemiological
factors is required. Furthermore, knowing the relationship between
these factors and the recurrence may increase the success rates of
the treatment. Although the aetiological, epidemiological and clini-
cal characteristics have been evaluated in previous studies, the
effects of these factors on the IGM recurrence have been poorly
analysed. Furthermore, the sample sizes of these studies were lim-
ited, as IGM is a rare disease. Although IGM is a chronic and recur-
rent disease, there is not much knowledge regarding the IGM
recurrence and the relationship of the chosen initial treatment. The
objectives of this study were to examine the demographic, sociocul-
tural and clinical characteristics observed among a large cohort of
IGM patients from Turkey and to identify factors related to the
recurrence of IGM.
Materials and methods
Our study was designed as a multicentric retrospective study, invol-
ving 22 breast centres in Turkey. The data of 720 patients who had
the treatment of IGM between January 2011 and March 2016 were
included in the study. Patient data were retrospectively obtained by
recording the data in patients’ files and electronic records based on
the protocol created initially for this study. Patients’ demographic,
clinical, radiological, treatment and recurrence of IGM-related char-
acteristics were recorded. Only the patients who were histopatholo-
gically diagnosed with IGM were included in this study. Exclusion
criteria included male patients, patients with breast carcinoma coex-
isted with IGM and non-IGM patients. Patients with tuberculous
mastitis were not included in the study. History of pulmonary tuber-
culosis, evidence of histologically tuberculous mastitis, positive
staining with Ziehl–Neelsen or acid-fast or positive tissue cultures
and chest X-ray findings consistent with previous tuberculosis find-
ings with positive tuberculin test were excluded in this study. The
return of a sign, symptom or disease after a remission was accepted
as recurrence. While there were no co-morbidities in 631 patients,
various co-morbidities were seen in 89 patients. The definition of a
city is a place with a population more than 100 000 habitants and
has better life conditions with a better healthcare accessibility; town
and village have less population with a limited source of healthcare
facilities. Previously diagnosed diseases were defined as chronic
diseases, such as hypertension, autoimmune disease and diabetes,
and patients were under the appropriate care. This study is regis-
tered at Clinicaltrials.gov by the number ID NCT02667132.
Statistical analysis
Continuous and categorical variable differences between the recur-
rence and no recurrence groups were analysed by t-test and chi-
square test, respectively. P-values <0.05 were considered as
statistically significant. All statistical analyses were conducted by
SAS/STAT version 9.3 (SAS Institute, Inc, Cary, NC, USA).
Results
A total of 720 IGM patients are included in the study mostly residing
in a city. Patient characteristics enrolled in the study are shown in
Table 1. The median age was 36 years (32–42). Median follow-up
was 16 (8, 33) months. A great majority of patients reported having
given birth and breastfeed. A quarter of the patients had a history of
smoking; however, the majority of them did not have any chronic dis-
eases and chronic medication use. Breast infection (30%) was more
common than systemic infection (11%) or lactation mastitis (18%).
The most common symptom was a mass with other symptoms in the
breast in 83% (n = 587) of patients, but the minority (7%, n = 50) of
patients had only erythema or fistula (Table 2). On physical examina-
tion, 75% of women had palpable mass (n = 538). Our findings
showed that IGM often located at upper left quadrant (28%, n = 202)
and only 5% of the cases were bilateral (Table 2). While 36%
(n = 258) of patients received only medical treatment, 8% (n = 60)
Table 1 Patient characteristics enrolled in the study
Percentage n (total
patients, n = 720)
Median age (25%, 75%) 36 (32, 42)
Median follow-up (months)
(25%, 75%)
16 (8, 33)
Patient’s place of residence
City 88 626
Town 9 66
Village 3 21
Education
Primary school 42 257
High school 36 218
University 12 76
None 10 58
Ever given birth 92 662
Ever breast fed 85 612
Oral contraceptive 13 90
Smoking 24 172
Chronic diseases
None 88 632
Hypertension 4 29
Autoimmune disease 3 21
Other 3 21
Diabetes 2 14
Coronary artery disease 0.4 3
Infection
Breast infection 30 216
Lactation mastitis 18 130
Systemic bacterial infection
history
11 81
Medication use
None 85 613
Others 10 71
Pain medicine 4 30
Herbal medicine 1 6
Systemic bacterial infection: bronchopneumonia, urinary system infections
and puerperal infections.
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received only surgical treatment. The combination of surgical and
medical treatment was administered to the majority of the patients
(56%, n = 398). The most frequent surgical treatment was wide local
excision with 69% (n = 323) followed by abscess drainage in 29%
(n = 137) and mastectomy in 1.3% (n = 6) (Table 3). Oral steroids
were the first choice for medical treatment (39%, n = 253) followed
by antibiotics in 37% (n = 240) and the combination of steroid and
antibiotics were given to 13% (n = 87) of the patients. Methotrexate
was given to only 1% (n = 5) of the patients. Ultrasound, mammogra-
phy and magnetic resonance imaging were used in 95% (n = 85),6
36% (n = 258) and 32% (n = 228) of the patients, respectively, and
67% (n = 300) of cases were scored as BIRADS 3.
The overall incidence rate of the first recurrence was 17%
(n = 122). IGM re-recurrence after treatment of patients was
3% (n = 22). Our results revealed that there are statistically sig-
nificant associations between IGM recurrence and pregnancy,
breastfeeding, smoking and history of breast infection
(P < 0.05). On the other hand, using an oral contraceptive,
chronic medication use, receiving various IGM treatment meth-
ods, education, chronic diseases, place of birth and place of
current residence were not found to be associated with IGM
recurrence (P > 0.05) (Table 4).
Discussion
IGM is a rare inflammatory disease of the breast. It generally affects
young women in their reproductive ages.1 The pathophysiology of
IGM is not clearly understood. However, the onset of some chemi-
cal reactions with oral contraceptive intake, infectious processes
and autoimmunity are considered to be involved.19
Table 2 Symptom and physical examination, and lesion localization
Percentage n (total
patients, n = 720)
Symptom
Mass 83 587
Pain 10 72
Other 7 50
Physical examination
Palpable mass 75 538
Abscess 42 302
Fistula 30 215
Axillary palpable
lymph node
7 50
Lesion localization
Left upper quadrant 28 202
Left lower quadrant 9 67
Right upper quadrant 23 166
Right lower quadrant 12 83
Central 13 90
Multiple quadrants 15 112
Table 3 Granulomatous mastitis-related clinical characteristics
Percentage n (total
patients, n = 720)
Unilateral 93 671
Bilateral 7 49
Pathological diagnosis
Tru-cut 62 437
Post-operative pathology 20 142
Excisional 7 52
Incisional 7 48
FNAB 4 30
Treatment
Only medical 36 258
Surgery then medical 33 234
Medical then surgery 23 164
Only surgery 8 60
Medical treatment
Antibiotic 37 240
Steroid 39 253
Steroid + antibiotic 13 87
Others 9 57
Antituberculosis therapy 2 12
Methotrexate 1 5
Surgical treatment
Wide local excision 69 323
Only abscess drainage 29 137
Mastectomy 1.3 6
Recurrence 17 122
Relapse after recurrence
therapy
3 22
FNAB, fine-needle aspiration biopsy.
Table 4 Comparison of demographic and clinical characteristics, and
treatment regimens between patient with and without IGM recurrence
Demographic IGM recurrence P-value
No
(n = 598)
Yes
(n = 122)
Median age (25%, 75%) 36 (32, 42) 35 (32, 41) 0.42
Patient’s place of residence, % (n) 0.11
Village 3 (20) 1 (1)
Town 9 (51) 13 (15)
City 88 (523) 87 (103)
Education, % (n) 0.83
Primary school 42 (209) 45 (48)
High school 36 (181) 35 (37)
University 9 (47) 10 (11)
None 13 (65) 10 (11)
Patient characteristics, % (n)
Pregnancy 91 (542) 98 (120) 0.0008
Breast feeding 84 (501) 91 (111) 0.03
Smoking 22 (132) 33 (40) 0.01
Oral contraceptive 12 (74) 13 (16) 0.80
Medication use, % (n) 0.7
None 85 (508) 86 (105)
Others 10 (58) 11 (13)
Pain medicine 5 (27) 2 (3)
Herbal medicine 1 (5) 1 (1)
Systemic bacterial infection
history, % (n)
12 (74) 6 (7) 0.02
Breast infection, % (n) 28 (170) 38 (46) 0.045
Chronic diseases, % (n) 0.52
None 88 (527) 85 (104)
Hypertension 4 (24) 4 (5)
Autoimmune disease 3 (15) 5 (6)
Other 3 (18) 2 (3)
Diabetes 1.7 (10) 3 (4)
Coronary artery disease 0.5 (3) 0 (0)
Treatment, % (n) 0.14
Only medical 37 (221) 30 (37) 0.14
Only surgery 8 (48) 10 (12) 0.53
Medical then surgery 22 (130) 28 (34) 0.15
Surgery then medical 33 (195) 32 (39) 0.85
IGM, idiopathic granulomatous mastitis.
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Although the possible aetiological factors of IGM have not been
certainly defined, some factors are believed to be effective,
which include autoimmune diseases, undetected microorganisms,
hyperprolactinaemia, diabetes and oral contraceptive use.14 However,
the exact factors have not been established yet. In addition to the
clinical characteristics of the disease, defining the relation of epide-
miological factors with IGM may be important in the prevention.
The studies of Aghajanzadeh et al. (n = 206),18 Al-Khaffaf et al.
(n = 133),20 Korkut et al. (n = 93),21 Akcan et al. (n = 74)13 and
Karanlik et al. (n = 60)17 with rather large series in the literature
were those in which some demographic characteristics could be
related to IGM. However, as far as our knowledge, our study has
the largest number with 720 IGM patients comparing the effects of
epidemiological–demographic–clinical factors on recurrence.
Various studies have reported an effect of ethnic origin and geo-
graphic region on the IGM prevalence.3,22 The prevalence of IGM has
been reported to be high in Turkey, Asia, and Far Eastern coun-
tries.13,17,21,23 In our study, all participants except six foreigners were
Turkish. We observed different prevalences in seven different geo-
graphic regions of Turkey. This finding indicates that IGM may be
observed in different frequencies within the same country as well.
IGM generally affects young women between 17 and 42 years of age.
The median age observed in our study was compatible with the litera-
ture.17,18,21 However, IGM may be observed in advanced ages such as
65 or 83 years as well.24 In agreement with a previous report,25 no sig-
nificant difference was observed between the recurrence and non-
recurrence groups according to the mean age in our study.
Although possible effects of antipsychotic drugs and drugs
increasing the prolactin level such as risperidone on IGM have been
demonstrated,26 we did not observe any relationship between pain
relievers, herbal, antihypertensive or antidiabetic medications and
IGM or IGM recurrence.
The relationship between living environment and IGM is not
well studied. In our study, 88% of the patients resided in a city. No
relation was observed between the region of birth and place of liv-
ing with the IGM recurrence. The findings observed in our study
were found to be compatible with those in the literature.27 In our
study, the educational statuses of the patients were mostly primary
school, which was followed by high school. No significant differ-
ence was observed between the educational status and the IGM
recurrence. In the study of Karanlik et al.17 investigating the effi-
cacy of steroids plus surgery in IGM, no significant difference was
observed between the groups with regard to the educational status.
However, the relation between the educational status and recurrence
has not been reported.
Although a possible connection between pregnancy, lactation and
IGM recurrence has been reported, their role in IGM pathophysiol-
ogy is not clear. Secretions, hormonal changes and inflammation dur-
ing pregnancy and lactation may be effective in the pathophysiology
of IGM. Localized autoimmune response against fat- and protein-rich
secretions may underly the mechanism of prolactin in IGM
pathogenesis.26,28–30 Furthermore, prolactin has been demonstrated
to cause granulomatous lesions, immune response and non-caseating
granulomas in both physiological and pathological actions.31 The
incidence of prolactinoma among patients with IGM has been
reported as 60–100/1 000 000.32 Furthermore, a high prolactin level
has been related to IGM recurrence.18 In one study, a history of preg-
nancy and lactating was observed in all patients with IGM except for
two among 43 patients.25 In another study, granulomatous mastitis has
been reported to be generally observed within several years following
delivery.33 In the study of Al-Khaffaf et al.,20 lactating was suggested
to be in the history of patients with long-term IGM. Evaluation of
patients with regard to the prolactin level and hypophysis adenoma is
recommended in granulomatous mastitis.28 The findings observed in
our study were found to be compatible with those in the literature.
Smoking is considered to be one of the possible aetiological factors
for IGM with no definite conclusion.13,20,23 Our results suggested a
significant relationship between smoking and IGM recurrence.
As oral contraceptives increase breast secretion, they are poten-
tial aetiological factors for IGM. Some studies demonstrate oral
contraceptive use among patients with IGM as much as 42.1%.
However, no precise relationship has been demonstrated between
oral contraceptive use and IGM.23 In our study, the oral contracep-
tive use was found to be 13% and no significant relationship was
found with the IGM recurrence.
The hypothesis that autoimmunity may cause IGM has long
been considered. The good response of IGM to steroid and immu-
nosuppressive agents, the T lymphocyte dominance in immuno-
histochemical studies and the similarity of granulomatous mastitis
to other autoimmune diseases, such as granulomatous thyroiditis
and granulomatous prostatitis, form the basis for this theory. How-
ever, due to the absence of immunological abnormalities in some
patients with granulomatous mastitis, this hypothesis has not been
completely confirmed. The recurrence observed despite the immu-
nosuppressive and steroid treatment in some of the patients with
IGM has not rendered autoimmunity alone to be responsible in
the aetiology.13 Furthermore, there is no sufficient evidence on
the relation between autoimmunity and granulomatous mastitis.
The role of autoimmune factors in the aetiology of IGM was not
demonstrated in the study of Altıntoprak et al.14 In our study,
autoimmune diseases were observed in only 3% of the patients
with IGM. No relationship was observed between the IGM recur-
rence and autoimmune diseases considered within the group of
chronic diseases.
There is a possible relationship between microbiological agents
and granulomatous mastitis. Corynebacterium has particularly
been blamed in the aetiology of granulomatous mastitis. Coryne-
bacterium was first encountered in 34 of 68 patients with histo-
pathologically diagnosed granulomatous mastitis by Taylor
et al.34 However, as Corynebacterium was not isolated from all
patients and its role in the aetiology of granulomatous mastitis is
not yet clear. In our study, 32% of the patients had breast infec-
tions caused by different bacterial agents. A significant relation-
ship was found between breast infection and the IGM recurrence.
The infections observed in the patients were not the ones that were
diagnosed at the time of the diagnosis of GM. These infections
were in the history of the patients. In patients with a history of
systemic bacterial infection, a significant relationship was
observed between the IGM recurrence and systemic bacterial
infection as well.
No correlation is observed between treatment methods and IGM
recurrence in our study. Treatment choice and sequence of IGM is
© 2017 Royal Australasian College of Surgeons
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still debated. Currently, there is no universally accepted treatment
strategy.13 Systemic corticosteroids and antibiotics are the most fre-
quently used agents in the medical treatment of IGM. However, suc-
cessful results have been reported with some agents, such as
methotrexate, azathioprine, glucocorticoids, bromocriptine and col-
chicine12 or combination with steroids.10 There are studies reporting
lower recurrence rates with broad surgical resection,19 while others
reporting an increased recurrence rate with surgical treatments.
There are certain limitations of our study: one of them was a
short duration of patient follow-up; longer follow-up is needed to
find out actual recurrence rate. As there were no enough records,
the interval between the breastfeeding and the onset of IGM in our
study was not evaluated. Collection data retrospectively is another
limitation of the study; there is no universal approach to diagnosis
and treatment of IGM among the study centres.
Conclusion
Our findings indicate that history of pregnancy, breastfeeding, breast
infection and smoking are risk factors for IGM recurrence. As treat-
ment methods examined in this study did not affect IGM recurrence,
future research should focus on less invasive local treatment options
and eliminate factors, such as breast infection and smoking.
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